Press Release

Cash position and revenue for Q1 2015

Toulouse, FRANCE, Ann Arbor, UNITED STATES, May 13, 2015 – **Cerenis Therapeutics** (**FR0012616852- CEREN)**, an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies ("good cholesterol") for treating cardiovascular and metabolic diseases, today announces its cash position and revenue for the first quarter of 2015.

In line with expectations, Cerenis Therapeutics did not record any revenue in Q1 2015. Efforts are currently focused on preparations for the launch of the clinical studies announced at the time of the Company's IPO in March. These clinical developments concern the phase II study for the post-ACS indication (CARAT) and the phase III study for the treatment of patients affected by Familial Hypoalphalipoproteinemia (FPHA) orphan disease, in particular patients with apoA-I and ABCA1 deficiencies (TANGO). The first patient enrolments for both studies are expected to take place throughout Q3 and Q4 2015, respectively. As a reminder, Cerenis Therapeutics is expecting the results of both studies by 2017, leading to a potential Market Authorization Application (AMM) for its flagship product, CER-001, by 2018 within the indication of the PFHA orphan disease.

On March 31, 2015, cash and cash equivalents totaled €54.8m*, including the gross product generated by the spectacular IPO that enabled the company to successfully raise €53.4m in March.

**Unaudited data*

Next financial press release: Cash position and revenue for H1 2015, on August 27, 2015.

About Cerenis Therapeutics: www.cerenis.com

Cerenis Therapeutics is an international biopharmaceutical company dedicated to the discovery and development of innovative HDL therapies for the treatment of cardiovascular and metabolic diseases. HDL is the primary mediator of the reverse lipid transport, or RLT, the only natural pathway by which excess cholesterol is removed from arteries and is transported to the liver for elimination from the body.
Cerenis is developing a portfolio of HDL therapies, including HDL mimetics for the rapid regression of atherosclerotic plaque in high-risk patients such as post-ACS patients and patients with HDL deficiency, and drugs which increase HDL for patients with low number of HDL particles to treat atherosclerosis and associated metabolic diseases.

Cerenis is well-positioned to become one of the leaders in the HDL therapeutic market, with a broad portfolio of programs being developed.

Since its inception in 2005, the company has been funded by top tier investors: Sofinnova Partners, HealthCap, Alta Partners, EDF Ventures, Daiwa Corporate Investment, TVM Capital, Orbimed, IRDI/IXO Private Equity and Bpifrance (Fund for Strategic Investment) and last March successfully completed an IPO on Euronext raising €53.4m.

About CER-001:

CER-001 is an engineered complex of recombinant human apoA-I, the major structural protein of HDL, and phospholipids. It has been designed to mimic the structure and function of natural, nascent HDL, also known as pre-beta HDL. Its mechanism of action is to increase apoA-I and the number of HDL particles transiently, to stimulate the removal of excess cholesterol and other lipids from tissues including the arterial wall and to transport them to the liver for elimination through a process called Reverse Lipid Transport.

CEREN LISTED EURONEXT

ELIGIBLE PEA PME

Contacts:

Cerenis
Jean-Louis Dasseux
CEO
info@cerenis.com
Tel: +33 (0)5 62 24 09 49

NewCap
Investors relations
Emmanuel Huynh / Louis-Victor Delouvrier
cerenis@newcap.fr
Tel: +33 (0)1 44 71 98 53

NewCap
Media relations
Nicolas Merigeau
cerenis@newcap.fr
Tel: +33 (0)1 44 71 94 98